| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-10 |
INHIBITS |
denotes |
Inhibition |
| E1-ti-1 |
14-30 |
cui:C0387583 |
denotes |
cyclooxygenase-2 |
| E2-ti-1 |
31-41 |
cui:C0185117 |
denotes |
expression |
| E3-ti-1 |
63-74 |
cui:C0243072 |
denotes |
derivatives |
| E4-ti-1 |
78-88 |
cui:C0036075 |
denotes |
salicylate |
| E5-ti-1 |
90-99 |
cui:C0077126 |
denotes |
triflusal |
| E6-ti-1 |
122-132 |
cui:C0870883 |
denotes |
metabolite |
| E7-ti-1 |
134-173 |
cui:C0048733 |
denotes |
2-hydroxy-4-trifluoromethylbenzoic acid |
| E1-ab-1 |
179-190 |
cui:C0302350 |
denotes |
therapeutic |
| E2-ab-1 |
191-200 |
cui:C0237399 |
denotes |
potential |
| E3-ab-1 |
204-209 |
cui:C0013227 |
denotes |
drugs |
| E4-ab-1 |
225-234 |
cui:C0857127 |
denotes |
induction |
| E5-ab-1 |
238-254 |
cui:C0387583 |
denotes |
cyclooxygenase-2 |
| E1-ab-2 |
281-284 |
cui:C0205448 |
denotes |
two |
| E2-ab-2 |
303-313 |
cui:C0036075 |
denotes |
salicylate |
| E3-ab-2 |
314-325 |
cui:C0243072 |
denotes |
derivatives |
| E4-ab-2 |
355-367 |
cui:C0053225 |
denotes |
benzoic acid |
| T3 |
355-378 |
ISA |
denotes |
benzoic acid (triflusal |
| T4 |
355-378 |
ISA |
denotes |
benzoic acid (triflusal |
| T5 |
355-378 |
ISA |
denotes |
benzoic acid (triflusal |
| T9 |
355-378 |
compared_with |
denotes |
benzoic acid (triflusal |
| E5-ab-2 |
369-378 |
cui:C0077126 |
denotes |
triflusal |
| E6-ab-2 |
401-411 |
cui:C0870883 |
denotes |
metabolite |
| E7-ab-2 |
414-451 |
cui:C0020317 |
denotes |
hydroxy-4-trifluoromethylbenzoic acid |
| T2 |
464-472 |
compared_with |
denotes |
compared |
| E8-ab-2 |
478-485 |
cui:C0004057 |
denotes |
aspirin |
| E9-ab-2 |
490-507 |
cui:C0037549 |
denotes |
sodium salicylate |
| E10-ab-2 |
511-546 |
cui:C1257954 |
denotes |
cyclooxygenase-2 (COX-2) inhibitors |
| T6 |
565-567 |
LOCATION_OF |
denotes |
in |
| E11-ab-2 |
568-577 |
cui:C0521009 |
denotes |
bacterial |
| E12-ab-2 |
578-596 |
cui:C0023810 |
denotes |
lipopolysaccharide |
| E13-ab-2 |
597-606 |
cui:C1515877 |
denotes |
activated |
| E14-ab-2 |
607-612 |
cui:C0020114 |
denotes |
human |
| E15-ab-2 |
613-618 |
cui:C0005767 |
denotes |
blood |
| E16-ab-2 |
620-629 |
cui:C0077126 |
denotes |
triflusal |
| E17-ab-2 |
631-638 |
cui:C0004057 |
denotes |
aspirin |
| E18-ab-2 |
644-647 |
cui:C0020317 |
denotes |
HTB |
| E19-ab-2 |
653-656 |
cui:C1518422 |
denotes |
not |
| E20-ab-2 |
657-674 |
cui:C0037549 |
denotes |
sodium salicylate |
| T7 |
676-685 |
DISRUPTS |
denotes |
inhibited |
| T8 |
676-685 |
DISRUPTS |
denotes |
inhibited |
| E21-ab-2 |
686-691 |
cui:C0387583 |
denotes |
COX-2 |
| E22-ab-2 |
692-700 |
cui:C0086597 |
denotes |
mediated |
| E23-ab-2 |
701-735 |
cui:C1514503 |
denotes |
prostaglandin E2 (PGE2) production |
| E24-ab-2 |
737-741 |
cui:C0600495 |
denotes |
IC50 |
| E1-ab-3 |
803-812 |
cui:C0077126 |
denotes |
triflusal |
| E2-ab-3 |
817-824 |
cui:C0004057 |
denotes |
aspirin |
| T10 |
825-834 |
INHIBITS |
denotes |
inhibited |
| T11 |
825-834 |
INHIBITS |
denotes |
inhibited |
| E3-ab-3 |
844-849 |
cui:C0387583 |
denotes |
COX-2 |
| E4-ab-3 |
850-856 |
cui:C0014442 |
denotes |
enzyme |
| E1-ab-4 |
871-879 |
cui:C0750489 |
denotes |
apparent |
| E2-ab-4 |
880-891 |
cui:C1290905 |
denotes |
discrepancy |
| E3-ab-4 |
910-913 |
cui:C0020317 |
denotes |
HTB |
| E4-ab-4 |
918-927 |
cui:C0077126 |
denotes |
triflusal |
| E5-ab-4 |
941-948 |
cui:C0004057 |
denotes |
aspirin |
| E6-ab-4 |
953-963 |
cui:C0036075 |
denotes |
salicylate |
| E7-ab-4 |
1014-1019 |
cui:C0387583 |
denotes |
COX-2 |
| E8-ab-4 |
1020-1038 |
cui:C1171362 |
denotes |
protein expression |
| T13 |
1039-1041 |
LOCATION_OF |
denotes |
in |
| E9-ab-4 |
1042-1052 |
cui:C0205100 |
denotes |
peripheral |
| E10-ab-4 |
1053-1058 |
cui:C0020114 |
denotes |
human |
| T12 |
1053-1076 |
PART_OF |
denotes |
human mononuclear cells |
| E11-ab-4 |
1059-1076 |
cui:C0806987 |
denotes |
mononuclear cells |
| E1-ab-5 |
1099-1106 |
cui:C1517331 |
denotes |
further |
| E2-ab-5 |
1122-1125 |
cui:C0034693 |
denotes |
rat |
| E3-ab-5 |
1126-1129 |
cui:C0001861 |
denotes |
air |
| E4-ab-5 |
1136-1141 |
cui:C0026336 |
denotes |
model |
| E5-ab-5 |
1165-1172 |
cui:C0004057 |
denotes |
aspirin |
| E6-ab-5 |
1177-1186 |
cui:C0077126 |
denotes |
triflusal |
| T14 |
1187-1196 |
DISRUPTS |
denotes |
inhibited |
| T15 |
1187-1196 |
DISRUPTS |
denotes |
inhibited |
| E7-ab-5 |
1197-1212 |
cui:C1514503 |
denotes |
PGE2 production |
| E8-ab-5 |
1270-1279 |
cui:C0077126 |
denotes |
triflusal |
| E9-ab-5 |
1280-1287 |
cui:C1522326 |
denotes |
treated |
| E10-ab-5 |
1288-1295 |
cui:C0003062 |
denotes |
animals |
| E11-ab-5 |
1305-1313 |
cui:C0547047 |
denotes |
decrease |
| E12-ab-5 |
1317-1322 |
cui:C0387583 |
denotes |
COX-2 |
| E13-ab-5 |
1323-1333 |
cui:C0185117 |
denotes |
expression |
| E1-ab-6 |
1340-1349 |
cui:C1547020 |
denotes |
different |
| E2-ab-6 |
1350-1358 |
cui:C0004927 |
denotes |
behavior |
| E3-ab-6 |
1379-1383 |
cui:C0449719 |
denotes |
part |
| E4-ab-6 |
1396-1403 |
cui:C0085732 |
denotes |
ability |
| E5-ab-6 |
1407-1410 |
cui:C0020317 |
denotes |
HTB |
| E6-ab-6 |
1415-1424 |
cui:C0077126 |
denotes |
triflusal |
| E7-ab-6 |
1456-1476 |
cui:C0040648 |
denotes |
transcription factor |
| E8-ab-6 |
1477-1484 |
cui:C0521447 |
denotes |
nuclear |
| E9-ab-6 |
1504-1510 |
cui:C0205250 |
denotes |
higher |
| E10-ab-6 |
1511-1517 |
cui:C0439792 |
denotes |
extent |
| E11-ab-6 |
1523-1530 |
cui:C0004057 |
denotes |
aspirin |
| E12-ab-6 |
1535-1552 |
cui:C0037549 |
denotes |
sodium salicylate |
| E1-ab-7 |
1563-1571 |
cui:C0442796 |
denotes |
addition |
| E2-ab-7 |
1575-1585 |
cui:C0311403 |
denotes |
inhibiting |
| E3-ab-7 |
1590-1595 |
cui:C0387583 |
denotes |
COX-2 |
| E4-ab-7 |
1596-1604 |
cui:C0439167 |
denotes |
activity |
| E5-ab-7 |
1608-1619 |
cui:C0302350 |
denotes |
therapeutic |
| E6-ab-7 |
1620-1634 |
cui:C0086045 |
denotes |
concentrations |
| E7-ab-7 |
1636-1645 |
cui:C0077126 |
denotes |
triflusal |
| T16 |
1636-1689 |
ISA |
denotes |
triflusal is able to block through its metabolite HTB |
| T18 |
1636-1689 |
INHIBITS |
denotes |
triflusal is able to block through its metabolite HTB |
| E8-ab-7 |
1649-1653 |
cui:C1299581 |
denotes |
able |
| T17 |
1657-1662 |
INHIBITS |
denotes |
block |
| E9-ab-7 |
1675-1685 |
cui:C0870883 |
denotes |
metabolite |
| E10-ab-7 |
1686-1689 |
cui:C0020317 |
denotes |
HTB |
| E11-ab-7 |
1694-1704 |
cui:C0185117 |
denotes |
expression |
| E12-ab-7 |
1708-1711 |
cui:C0205314 |
denotes |
new |
| E13-ab-7 |
1712-1718 |
cui:C0014442 |
denotes |
enzyme |
| E14-ab-7 |
1748-1752 |
cui:C0012472 |
denotes |
PGE2 |
| E15-ab-7 |
1753-1762 |
cui:C0869032 |
denotes |
synthesis |
| E1-ab-8 |
1764-1773 |
cui:C0077126 |
denotes |
Triflusal |
| E2-ab-8 |
1778-1781 |
cui:C0020317 |
denotes |
HTB |
| E3-ab-8 |
1803-1810 |
cui:C1280500 |
denotes |
effects |
| E4-ab-8 |
1814-1823 |
cui:C1522240 |
denotes |
processes |
| T19 |
1824-1826 |
COEXISTS_WITH |
denotes |
in |
| T20 |
1824-1826 |
COEXISTS_WITH |
denotes |
in |
| E5-ab-8 |
1833-1840 |
cui:C1515568 |
denotes |
de novo |
| E6-ab-8 |
1841-1846 |
cui:C0387583 |
denotes |
COX-2 |
| E7-ab-8 |
1847-1857 |
cui:C0185117 |
denotes |
expression |
| E8-ab-8 |
1880-1887 |
cui:C0332464 |
denotes |
broader |
| E9-ab-8 |
1898-1910 |
cui:C1521733 |
denotes |
pathological |
| E10-ab-8 |
1931-1936 |
cui:C0017337 |
denotes |
genes |
| E11-ab-8 |
1943-1950 |
cui:C0521447 |
denotes |
nuclear |
| E12-ab-8 |
1951-1957 |
cui:C1521761 |
denotes |
factor |
| E13-ab-8 |
1965-1972 |
cui:C0243148 |
denotes |
control |
| R1 |
E4-ti-1 |
T1 |
subjectOf |
salicylate,Inhibition |
| R10 |
E7-ab-2 |
T5 |
objectOf |
hydroxy-4-trifluoromethylbenzoic acid,benzoic acid (triflusal |
| R11 |
E15-ab-2 |
T6 |
subjectOf |
blood,in |
| R12 |
E10-ab-2 |
T6 |
objectOf |
cyclooxygenase-2 (COX-2) inhibitors,in |
| R13 |
E20-ab-2 |
T7 |
subjectOf |
sodium salicylate,inhibited |
| R14 |
E23-ab-2 |
T7 |
objectOf |
prostaglandin E2 (PGE2) production,inhibited |
| R15 |
E9-ab-2 |
T8 |
subjectOf |
sodium salicylate,inhibited |
| R16 |
E23-ab-2 |
T8 |
objectOf |
prostaglandin E2 (PGE2) production,inhibited |
| R17 |
E5-ab-2 |
T9 |
subjectOf |
triflusal,benzoic acid (triflusal |
| R18 |
E8-ab-2 |
T9 |
objectOf |
aspirin,benzoic acid (triflusal |
| R19 |
E2-ab-3 |
T10 |
subjectOf |
aspirin,inhibited |
| R2 |
E1-ti-1 |
T1 |
objectOf |
cyclooxygenase-2,Inhibition |
| R20 |
E3-ab-3 |
T10 |
objectOf |
COX-2,inhibited |
| R21 |
E1-ab-3 |
T11 |
subjectOf |
triflusal,inhibited |
| R22 |
E3-ab-3 |
T11 |
objectOf |
COX-2,inhibited |
| R23 |
E11-ab-4 |
T12 |
subjectOf |
mononuclear cells,human mononuclear cells |
| R24 |
E10-ab-4 |
T12 |
objectOf |
human,human mononuclear cells |
| R25 |
E11-ab-4 |
T13 |
subjectOf |
mononuclear cells,in |
| R26 |
E7-ab-4 |
T13 |
objectOf |
COX-2,in |
| R27 |
E6-ab-5 |
T14 |
subjectOf |
triflusal,inhibited |
| R28 |
E7-ab-5 |
T14 |
objectOf |
PGE2 production,inhibited |
| R29 |
E5-ab-5 |
T15 |
subjectOf |
aspirin,inhibited |
| R3 |
E7-ab-2 |
T2 |
subjectOf |
hydroxy-4-trifluoromethylbenzoic acid,compared |
| R30 |
E7-ab-5 |
T15 |
objectOf |
PGE2 production,inhibited |
| R31 |
E7-ab-7 |
T16 |
subjectOf |
triflusal,triflusal is able to block through its metabolite HTB |
| R32 |
E10-ab-7 |
T16 |
objectOf |
HTB,triflusal is able to block through its metabolite HTB |
| R33 |
E7-ab-7 |
T17 |
subjectOf |
triflusal,block |
| R34 |
E10-ab-7 |
T17 |
objectOf |
HTB,block |
| R35 |
E7-ab-7 |
T18 |
subjectOf |
triflusal,triflusal is able to block through its metabolite HTB |
| R36 |
E7-ab-7 |
T18 |
objectOf |
triflusal,triflusal is able to block through its metabolite HTB |
| R37 |
E2-ab-8 |
T19 |
subjectOf |
HTB,in |
| R38 |
E6-ab-8 |
T19 |
objectOf |
COX-2,in |
| R39 |
E1-ab-8 |
T20 |
subjectOf |
Triflusal,in |
| R4 |
E8-ab-2 |
T2 |
objectOf |
aspirin,compared |
| R40 |
E6-ab-8 |
T20 |
objectOf |
COX-2,in |
| R5 |
E5-ab-2 |
T3 |
subjectOf |
triflusal,benzoic acid (triflusal |
| R6 |
E4-ab-2 |
T3 |
objectOf |
benzoic acid,benzoic acid (triflusal |
| R7 |
E5-ab-2 |
T4 |
subjectOf |
triflusal,benzoic acid (triflusal |
| R8 |
E18-ab-2 |
T4 |
objectOf |
HTB,benzoic acid (triflusal |
| R9 |
E5-ab-2 |
T5 |
subjectOf |
triflusal,benzoic acid (triflusal |